Rockefeller Capital Management
BLRX

Rockefeller Capital Management’s BioLineRX BLRX Stock Holding History

Rockefeller Capital Management’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12
Closed -$28 – 4745
2026
Q1 		$28 Hold
12
– – ﹤0.01% 4657
2025
Q4 		$33 Hold
12
– – ﹤0.01% 4650
2025
Q3 		$45 Buy
+12
New +$48 ﹤0.01% 4398

Other funds holding BLRX

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
BCV
Banque Cantonale Vaudoise Lausanne, Switzerland $722M AUM 30.45% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.21B AUM 33.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Rockefeller Capital Management's BLRX Position: Q2 2026 in Review

Rockefeller Capital Management sold out of BioLineRX (BLRX) in Q2 2026, closing a stake of 12 shares — an estimated $28 sold.

Rockefeller Capital Management first reported a position in BLRX in Q3 2025 and held it in 3 quarters. The position peaked at $45 in Q3 2025. 14 funds tracked by Wall St. Rank hold BLRX as of Q2 2026.

  • Rockefeller Capital Management reported no remaining BioLineRX position as of Q2 2026 after selling out during the quarter.
  • Rockefeller Capital Management sold 12 BioLineRX shares in Q2 2026, an estimated $28.
  • Rockefeller Capital Management first reported a position in BioLineRX in Q3 2025 and held it in 3 quarters.
  • Rockefeller Capital Management's BioLineRX position peaked at $45 in Q3 2025.
  • 14 funds tracked by Wall St. Rank held BioLineRX as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.